LONDON--(BUSINESS WIRE)--Technavio’s latest report on the global angina pectoris drugs market provides an analysis on the most important trends expected to impact the market outlook from 2017-2021.

In January 2006, the U.S. Food and Drug Administration (FDA) approved a new antianginal agent for the treatment of chronic stable angina, ranolazine (Ranexa™; CV Therapeutics, Inc.). The drug, ...

The goals of treatment are to decrease the frequency of angina, increase longevity, and improve patients' QOL. Management of risk factors is an essential component of this therapy. Also important is ...

Learn about angina, its types, symptoms, causes, diagnosis, and treatment. Understand ischemic chest pain and how to manage ...

When a robust man suddenly drops dead and the newspapers report “heart failure,” the probability is that he died during an attack of angina pectoris. If he had gone to his doctor the day before, the ...

Clinical trials in human beings are in progress on using heart drugs for the treatment of bipolar disorder following its successful trials in cells and rats, said neuroscientist Dr Jee Hyun Kim, ...

who no longer responds to standard drugs or surgery. This marks the next step in bringing a new option to patients who live with constant, disabling heart pain. Angina pectoris — chest pain from ...